News

Article

The Center for Breakthrough Medicines Announces Plasmid Manufacturing Service

CBM’s plasmid manufacturing offering is designed to provide phase-appropriate plasmids on demand for companies working on cell and gene therapies.

The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization, announced the launch of its plasmid manufacturing offering, Precision Plasmids, on Feb. 2, 2023. The service is designed to provide phase-appropriate plasmids on demand for companies working on cell and gene therapies.

According to a company press release, the service uses next-generation sequencing to guarantee reproducibility of vector-based therapies that are manufactured using plasmids. Expected turnaround times are 12 weeks for plasmids from a good manufacturing practice (GMP) master bank, or 17+ weeks for those working from a starting R&D plasmid.

“As a starting material for mRNA [messenger RNA] vaccines and key components for vector-based cell and gene therapies, plasmids are in high demand for the foreseeable future,” said Dana Cipriano, senior-vice-president, Testing and Analytical Services & Plasmids, CBM, in the release. “CBM’s Precision Plasmids solve the capacity challenge by bringing a platform process, multiple scales, and segregated suites to meet any clinical and commercial production needs on demand.”

The plasmids are offered in three varieties: R&D, Pro, and GMP. The R&D plasmids grade for pre- and early clinical phases, while the Pro grade for toxicology studies, Phase I to II vector production, or as a starting material for mRNA. GMP grade services are expected to launch in April 2023.

Source: Center for Breakthrough Medicines

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content